Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107900 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 606
- Enrollment target
NCT00107900 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 606 participants.
The verdict
NCT00107900, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 606 participants
- Enrollment target
Study Summary
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the occurrence of deep vein thrombosis in patients having total hip replacement surgery.
Interventions
- DRUG DU-176b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107900
The ClinicalTrials.gov registry entry for NCT00107900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DU-176b is the first listed.
NCT00107900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107900 about?
NCT00107900 is a clinical study titled "Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement". Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the occurrence of deep vein thrombosis in patients having total hip replacemen...
What is the current status of trial NCT00107900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 606 participants. The study started on 2005-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00107900?
The interventions under investigation include: DU-176b (DRUG).
Who is sponsoring clinical trial NCT00107900?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.